Drawing for Serial No. 87824828

USPTO serial 87824828

Serial No. 87824828

Reviewed by CopyMark Law Group

Reg. 5754634Status 705Registered
Filing date
Status date
Registration date
May 21, 2019
Examiner
BEAUDRY-TORRES, FAITH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with Serial No. 87824828?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan A. Hyman

Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and medicinal preparations and substances for the treatment of [ cancer, thrombosis, embolisms, inflammation, autoimmune diseases, and ] envenomation by snakes; veterinary preparations and substances for the treatment of envenomation by snakes; sanitary preparations for medical purposes; dietetic foods adapted for medical use; vaccines; antitoxic sera; medical diagnostic reagents and substances, all for in vivo use; [ Antibodies being therapeutic antibodies for use as anti-lymphocytic agents; pharmaceutical preparations in the form of foams or for use in producing foams for the treatment of sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical or veterinary purposes; ] chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes, methotrexate toxicity, 5-fluorouracil toxicity; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; [ chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial hemorrhages, cerebral hemorrhages, hematomas, and as antidotes; pharmaceutical preparations for the treatment of cancer; ] pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of immune disorders; [ pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; pharmaceutical preparations for the treatment of sepsis; ] preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; [ pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; ] adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; [ pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical or veterinary therapeutic and medical diagnostic purposes; ] chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity [ , and for use in the treatment of pre-eclampsia ] ; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity [ and for use in the treatment of pre-eclampsia ] ; [ transarterial chemoembolization pharmaceutical preparations, vaccines and antitoxic sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; pharmaceutical preparations, being beads, including microscopic radioactive beads, for treatment of cancerous tumours; pharmaceutical preparations, being beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; pharmaceutical preparations, being beads, namely, radioactive glass beads; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; ] pharmaceutical preparations containing methotrexate antidotes for the treatment of methotrexate toxicity; pharmaceutical preparations containing 5-fluorouracil antidotes for the treatment of 5-fluorouracil toxicity; pharmaceutical preparations for use in chemotherapy and autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agentsACTIVE—
010[ Surgical, medical, dental and veterinary apparatus and instruments, namely, cryoablation needles, medical syringes, electrically powered tissue ablation devices, surgical and medical apparatus and instruments for the treatment and prevention of varicose veins, arterio-venous malformations, oesophageal varices, hydroceles, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, intracranial haemorrhages, cerebral haemorrhages, hematomas, peripheral vascular lesions and coronary vascular lesions, devices for intravenous administration of pharmaceutical foam, and diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose, surgical and medical apparatus and instruments for use in minimally invasive cryoablation procedures; artificial limbs; orthopaedic articles, namely, implants made of artificial materials; medical syringes, medical cannula needles, medical tubing; surgical and medical apparatus for producing and administering foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical or medical apparatus for producing foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical devices for assessing the physical characteristics of foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices or hydroceles, namely, devices for intravenous administration of foam and devices for monitoring the position and effect of foam in the human body; medical diagnostic devices for diagnosing, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; haemofiltration devices for medical use; drug delivery embolisation apparatus, instruments and devices; apparatus and instruments for use in the circulatory system; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems, namely, surgical and medical instruments for embolisation; drug delivery embolisation devices and instruments; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic glass beads, impregnated with radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices which use ultrasound to enhance drug delivery and/or medically activate drugs; catheters for delivery of drugs or fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology or proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; medical devices for assessing the physical characteristics of sclerosing foams; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of foam in the human body; medical diagnostic apparatus for diagnosing varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; surgical apparatus and instruments, medical devices and medical diagnostic apparatus and instruments for use in interventional pulmonology; medical devices for use in pulmonary and thoracic surgery and procedures; lung volume reduction medical devices; artificial surgical implants for use in interventional pulmonology; surgical implants comprising artificial surgical implants for restoring, maintaining and improving patient breathing, and artificial surgical implants for restoring, maintaining and improving lung function; catheters for use in cardiology; catheters for use in the treatment of arterial diseases; cryoablation needles for medical use; Medical apparatus and instruments, namely, cryoablation apparatus for the treatment of tumours and management of pain; replacement and structural parts and fittings for all of the aforesaid goods ]SECTION 8 - CANCELLED—
041[ Education, namely, providing on-line instruction in the fields of healthcare, the use of pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; providing online databases featuring education information about medical education in the fields of healthcare, the use of pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; education services, namely, providing instruction, workshops, seminars, continuing education and training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; arranging, and conducting educational conferences and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; provision and publication of educational material and content, namely, teaching guides, instructional materials, brochures and pamphlets in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; providing on-line non-downloadable publications in the nature of teaching guides, instructional materials, brochures and pamphlets in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; providing online, non-downloadable electronic publications, namely, patient reported outcome questionnaires in the fields of healthcare, medicine, medical treatment and patient care; conducting educational seminars in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials therewith; information and advice relating to educational training provided online from a computer database or the internet, all relating to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 4, 2025C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 4, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 6, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Feb 14, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 14, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 14, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 14, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 14, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 21, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 13, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 13, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 13, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 16, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 16, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 16, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 16, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 16, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 12, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 12, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 12, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Apr 12, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 12, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 12, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 30, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 30, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 30, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 30, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 30, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 14, 2021ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Aug 29, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 29, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 29, 2020EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Aug 29, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 29, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 29, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 21, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 5, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 5, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 13, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 31, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 31, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Jan 31, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 31, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 31, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 15, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Jan 15, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 15, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 15, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 14, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 13, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 13, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 28, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 28, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 28, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 19, 2018DOCKASSIGNED TO EXAMINER—
Jun 19, 2018DOCKASSIGNED TO EXAMINER—
Apr 2, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Mar 29, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Mar 29, 2018ALIEASSIGNED TO LIE—
Mar 15, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 14, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 14, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 12, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 10, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance